Cell & Gene Therapy clinical development solutions to reduce scientific, regulatory and commercial risks, and accelerate development wherever you are in your product's development.

1. CELL & GENE THERAPY
Clinical Development Solutions
With specialized expertise, coordinated capabilities and focused
investments across preclinical, clinical and post-approval phases, we’ll help
you to reduce the time and risk in your product’s development.
Supported the development of
BOTH
GENE
REPLACEMENT
THERAPIES
FDA approved
CAR-T therapies and helped
advance the first 2 FDA-approved
Clinical Studies
Unique datasets
- Ideal site selection
- Optimal patient recruitment
- More accurate forecasting
Expertise in oncology, immuno-oncology,
rare diseases and pediatrics
Protocol modeling
Project management and oversight
Medical monitoring and specialized training for AEs
First in Human/dose range-finding
Proof of Mechanism/Proof of Concept (PoM/PoC)
Long-term follow-up and testing strategy
Conducted for cell and gene
products across the U.S.,
Europe and Asia
Conducted with 1,450+
patients across 333 sites in the
U.S. and Europe
Conducted using gene (7)
and cell (9) therapies
Biomarkers
Strategy
Assay development
RUO regulated testing
Genomics and proteomics
Specialty services
Companion diagnostics
Central Labs
Kits
Logistics
Safety testing
Genomics and flow
cytometry
Nimble handling of time-
sensitive samples globally
Bioanalysis
Biodistribution, persistence
and shedding of product or
transgene
QPCR, flow cytometry
and ELISA
Immunogenicity
assessment– NAb assays
In the last 4 years:
42+
CLINICAL STUDIES
16RARE DISEASE STUDIES
12CAR-T STUDIES

2. CELL GENE THERAPY
Clinical Development Solutions
Regulatory Strategic Product
Development Consulting
Clinical development plan
Target product profile
Regulatory agency interactions
Integrated development strategies
focused on value inflection points
Differentiation strategy
Study design/protocol development
Global labeling
Regulatory review and registration path
Dossier assembly, publishing and submission
CMC Analytical Testing
Analytical control strategy development
Phase-appropriate method development
and validation
Safety, identity, strength, quality and
purity testing
Comparability of preclinical and
clinical lots
Lot release and stability
Commercialization
Market access and strategy
Value communication
Evidence generation
Post-Approval Planning
Real-world evidence
Post-marketing commitments
Long-term follow-up
Patient and field support
Patient safety and pharmacovigilance
Submissions in the last
5 years, and 67 in prior
positions for strategists
PMs (all product types
and therapeutic areas)
11NDA/MAA
analytical development
and testing across the
U.K. and U.S.
3GMP LABS
SUPPORTING
in the U.S., Europe and
Asia Pacific
~80CMA CONSULTANTS
currently for patient
field support of
100+ products (all product
types and therapeutic areas)
50+
SERVICE
PROGRAMS
Precision Medicine Solutions Designed Around You®
Visit us at www.covance.com/CGT
Covance is the drug, medical device and diagnostics business segment of LabCorp, a leading
global life sciences company. COVANCE is a registered trademark and the marketing name for
Covance Inc. and its subsidiaries around the world.
The Americas +1.888.COVANCE (+1.888.268.2623) +1.609.452.4440
Europe / Africa +00.800.2682.2682 +44.1423.500888
Asia Pacific +800.6568.3000 +65.6.5686588
© Copyright 2019 Covance Inc. SSCGT002-0819